GI Dynamics Announces New EndoBarrier® Data from Research with GlaxoSmithKline Presented during Digestive Disease Week

Published: May 05, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

GI Dynamics, Inc. (ASX: GID), a medical device company developing innovative treatments for type 2 diabetes and obesity, today announced that new data from a study with GlaxoSmithKline (NYSE: GSK) on EndoBarrier® and its potential mechanism of action were presented at Digestive Disease Week 2014 (DDW) during an oral presentation titled, “Duodenal-jejunal Bypass Liner Increases Fasting and Postprandial Serum Levels of Bile Acids in Patients with Severe Obesity.”

Help employers find you! Check out all the jobs and post your resume.

Back to news